Assessment of Baseline Plasma p‐tau217 in TANGO, a Randomized, Placebo‐controlled Phase 2 Study of Gosuranemab in Patients with Early Alzheimer’s Disease
Julie Czerkowicz, Rong Zhang, Jessica Collins, Carrie E. Rubel, John O'Gorman, Melanie Shulman, Danielle Graham · 2025
Read Assessment of Baseline Plasma p‐tau217 in TANGO, a Randomized, Placebo‐controlled Phase 2 Study of Gosuranemab in Patients with Early Alzheimer’s Disease by Julie Czerkowicz, Rong Zhang, Jessica Collins, Carrie E. Rubel, John O'Gorman, Melanie Shulman, Danielle Graham (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712753.txt.
Description
Julie Czerkowicz and co-authors published a research paper in 2025 on a blood marker measured in a trial of an anti-tau drug for early Alzheimer's disease. The trial drug, gosuranemab, bound its target well but failed to slow the illness. The team went back to stored blood to test whether a marker called p-tau217 could pick out true cases and forecast decline.
Blood from 554 trial members was tested with a sharp counting assay, and many also had tau and amyloid scans. The marker tracked closely with a sister marker and with amyloid scan load at the start. Work like this helps future trials use a blood draw, not costly scans, to screen patients.
Catalog record
| CREATOR | Julie Czerkowicz, Rong Zhang, Jessica Collins, Carrie E. Rubel, John O'Gorman, Melanie Shulman, Danielle Graham |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |